Theravectys

What Theravectys does

TheraVectys is a French clinical-stage biotechnology company founded in 2005 and headquartered in Paris, with a US subsidiary in St Pete Beach, Florida. It is a spin-off from Institut Pasteur operating under an exclusive worldwide licensing agreement on the Institut Pasteur's lentiviral vector patent portfolio for vaccine applications in humans and animals, including DNA flap technology. The company has 11–50 employees and is privately held, backed principally by Tethys Invest SAS, with reported cumulative funding of approximately $51M across four disclosed rounds between 2012 and 2021. In January 2026, Bloomberg reported that TheraVectys is considering a Hong Kong IPO that could raise several hundred million US dollars.

The company's core offering is a proprietary, non-integrative lentiviral vector immunotherapy platform engineered for in vivo dendritic cell targeting. The vectors do not integrate into host cell DNA and use DNA flap technology to deliver genetic material into the nucleus of non-dividing cells, including dendritic cells, which the company describes as a property unique to lentiviral vectors. The platform reportedly induces strong, diversified, and long-lasting T-cell and antibody-mediated immunity without adjuvant, with low active dose and dry-freezing-compatible distribution. Pipeline programs include Lenti-HPV-07 (Phase I/IIa in HPV-induced cervical and oropharyngeal cancers, first patient enrolled February 2026 under NCT02054286), therapeutic hepatitis B (Phase I in China via partner Shanghai Jinwei Biotechnology), prostate and liver cancer programs, prophylactic vaccines against HIV, malaria, tuberculosis and emerging diseases, and a SARS-CoV-2 / pan-coronavirus candidate. Preclinical data include 100% protection against SIV in macaques, complete tumor eradication on single vaccination in HPV cancer models, and greater than 1,000-fold reduction in lung viral load after nasal SARS-CoV-2 instillation.

TheraVectys is pre-revenue and monetizes through future commercialization of therapeutic and prophylactic vaccines, supplemented by R&D, manufacturing, and clinical collaborations. Clinical development is conducted either directly or via collaboration, supported by an international network including the Institut Pasteur Joint-Laboratory established June 2017 and reinforced by a 2019 licensing expansion covering GMP production and the next 10 years of platform innovation. The company currently reaches its scientific and clinical audiences through peer-reviewed publications (e.g., EMBO Molecular Medicine), clinical trial registrations, and academic/industry partnerships rather than traditional commercial channels. End customers are patients with HPV-induced cancers, chronic HBV, and other infectious diseases, served indirectly through healthcare providers following regulatory approval.

Name

Theravectys

Legal name

TheraVectys SA

Website

https://theravectys.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

TheraVectys is a Paris-based clinical-stage biotech developing proprietary non-integrative lentiviral vector vaccines for therapeutic and prophylactic use against HPV-induced cancers, hepatitis B, HIV, malaria, and SARS-CoV-2. The company is a Pasteur Institute spin-off conducting Phase I/IIa trials and is considering a Hong Kong IPO.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccine Development

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Lentiviral Vector Gene Therapy Developers (HLAAACAB)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Lentiviral vector vaccines
• Therapeutic cancer vaccines
• HPV-induced cancer immunotherapy
• Infectious disease vaccines
• Clinical-stage biotechnology

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Vaccine Development and Commercialization: Pre-revenue clinical stage biotech company developing lentiviral vector-based vaccine candidates for prevention and treatment of cancer and infectious diseases. Revenue would come from successful commercialization of therapeutic and prophylactic vaccines upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

TheraVectys develops a proprietary non-integrative lentiviral vector immunotherapy platform used to design and advance therapeutic and prophylactic vaccine candidates for cancers and infectious diseases. Its lead clinical asset, Lenti-HPV-07, is in Phase I/IIa trials targeting HPV-induced cervical and oropharyngeal cancers, supported by pipeline programs covering hepatitis B, HIV, malaria, and SARS-CoV-2 / pan-coronavirus indications.

Product overview

TheraVectys is a French clinical-stage biotechnology company that is spun off from Institut Pasteur. It operates as a single unified platform company built around its proprietary non-integrative lentiviral vector immunotherapy technology. The company's product portfolio is organized into four pipeline programs — Oncology (featuring Lenti-HPV-07 in Phase I/IIa, plus prostate and liver cancer programs), Therapeutic Infectious Diseases (hepatitis B in Phase I, HIV), Prophylactic Infectious Diseases (HIV, malaria, Zika), and Emerging Diseases (SARS-CoV-2 and pan-coronavirus T-cell vaccines) — all powered by the same core lentiviral vector platform that enables in-vivo dendritic cell targeting and strong, long-lasting T-cell immunity. Development is pursued both directly and through international partnerships including Institut Pasteur and Shanghai Jinwei Biotechnology.

Differentiator

Problem solved

Functional benefit

Products and services

• Lenti-HPV-07 Lentiviral vector-based therapeutic vaccine targeting human papillomavirus (HPV)-induced cancers, including cervical and oropharyngeal cancers. Administered intramuscularly, it demonstrated 100% preclinical efficacy in eradicating HPV-induced tumors in animal models.
• TheraVectys Lentiviral Vector Immunotherapy Platform Proprietary, non-integrative lentiviral vector platform engineered for in-vivo dendritic cell targeting. The platform induces strong, diversified, and long-lasting cellular (T-cell) and antibody-mediated immune responses for therapeutic and prophylactic vaccination across oncology and infectious disease indications.
• Prophylactic Infectious Diseases Program Preclinical and clinical programs focused on preventive vaccination against major infectious diseases, including HIV (SIV model), malaria, and Zika virus, using the proprietary lentiviral vector platform.
• Therapeutic Infectious Diseases Program Therapeutic vaccination programs targeting chronic infectious diseases including hepatitis B (HBV) and HIV, with Phase I clinical trials on hepatitis B conducted in China via partner Shanghai Jinwei Biotechnology.
• Emerging Diseases Program (SARS-CoV-2 / Pan-Coronavirus) Second-generation COVID-19 vaccine candidates (Lenti-Covid) generating durable cellular T-cell responses against SARS-CoV-2 and its variants, including pan-coronavirus approaches, with nasal instillation delivery demonstrating >1,000-fold reduction in lung viral load in preclinical models.
• Prostate Cancer Program Preclinical program preparing for Phase I/IIa clinical trials targeting prostate cancer using the lentiviral vector immunotherapy platform.
• Liver Cancer Program Phase I clinical trials on liver cancer planned in China through partner Shanghai Jinwei Biotechnology, leveraging the company's lentiviral vector technology.

Quantifiable outcome

• 100% protection against SIV (HIV equivalent in monkeys) in macaque model - best protection ever described in this predictive model
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Institut PasteurcoreStrategic or Co-development Partner · 1 January 2007TheraVectys and Institut Pasteur entered an exclusive and global licensing agreement on the patent portfolio for vaccine applications in humans and animals in 2007. In 2019, this agreement was reinforced and expanded to include industrial production of GMP lots and future innovations for the next 10 years. TheraVectys is a spin-off from Institut Pasteur with historically very strong partnership.
• Shanghai Jinwei BiotechnologycoreStrategic or Co-development PartnerPhase I clinical trials on hepatitis B and liver cancer being conducted in China by TheraVectys partner Shanghai Jinwei Biotechnology under two existing collaboration agreements. Extremely promising initial results reported.
• Pasteur Institute-TheraVectys Joint-LaboratorycoreStrategic or Co-development PartnerCreated in June 2017 to focus the company on core business, pre-clinical research and reinforce collaboration with the Institut Pasteur. The Joint-Laboratory conducts proof of concept studies and builds a solid portfolio of potential candidates for clinical developments.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Transgene: French clinical-stage biotech developing viral vector-based immunotherapies, including lentiviral and vaccinia-based therapeutic cancer vaccines (e.g., myvac, TG4050). Most directly comparable to TheraVectys in both technology platform (viral vector vaccines) and target indications (HPV, oncology therapeutic vaccines).
• Hookipa Pharma: Clinical-stage biotech developing arenaviral vector-based prophylactic and therapeutic vaccines against infectious diseases (HBV, HIV) and oncology. Directly comparable to TheraVectys in using viral vector platforms to elicit T-cell immunity for therapeutic and prophylactic vaccination.
• Oxford BioMedica: UK-based specialist in lentiviral vector development and manufacturing with a leading LentiVector platform used for CAR-T and gene therapies. Directly comparable to TheraVectys in lentiviral vector technology, with overlapping GMP manufacturing and DNA flap / vector engineering expertise.
• ImmunityBio: US clinical-stage biotech developing therapeutic cancer vaccines and immunotherapies including Anktiva for HPV-related cancers. Comparable to TheraVectys in therapeutic cancer vaccine focus and HPV-induced cancer indication overlap, though using different technology platforms.
• Lentigen Technology (Miltenyi Biotec): Specialized developer of lentiviral vector technologies for cell and gene therapy applications, now part of Miltenyi Biotec. Comparable to TheraVectys in lentiviral vector technology core expertise, with focus on gene-modified cell therapies rather than vaccines.

Emerging players

• Themis Bioscience: Vienna-based biotech (acquired by Merck KGaA) that developed lentiviral vector-based vaccines against infectious diseases including SARS-CoV-2 and chikungunya. Comparable to TheraVectys in lentiviral vector vaccine platform technology for infectious disease prophylaxis.

Broad incumbents

• VIR Biotechnology: Clinical-stage immunology company developing therapeutics for serious infectious diseases including HBV, HIV, and SARS-CoV-2. Comparable to TheraVectys in therapeutic vaccine / antibody focus on chronic infectious diseases, especially HBV and HIV indications.
• Bavarian Nordic: Established commercial-stage vaccine company with approved products (e.g., JYNNEOS for mpox/smallpox) and infectious disease pipeline including HPV and RSV programs. Comparable to TheraVectys in vaccine development focus and infectious disease prophylaxis scope.
• Moderna: Commercial-stage biotech with approved mRNA vaccines (Spikevax) and a pipeline including mRNA cancer vaccines and prophylactic vaccines against infectious diseases. Comparable to TheraVectys in therapeutic cancer vaccine and infectious disease prophylaxis scope, though using mRNA rather than viral vector technology.
• BioNTech: Commercial-stage biotech with approved COVID-19 mRNA vaccine (Comirnaty) and a pipeline of mRNA-based cancer vaccines (e.g., BNT122/autogene cevumeran) and infectious disease programs. Comparable to TheraVectys in therapeutic cancer vaccine focus and infectious disease pipeline breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/theravectys
• LinkedInlinkedin.com/company/theravectys

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theravectys